St Jude receives warning letter for Sylmar plant
Jan 14 (Reuters) - St Jude Medical Inc said it had received a warning letter from U.S. health officials concerning manufacturing issues at its Sylmar, California, plant, where it makes cardiac rhythm management devices.
In October, the company disclosed that it might receive such a letter from the U.S. Food and Drug Administration.
In a regulatory filing on Monday, St Jude said the FDA had noted in the letter that it would not approve certain new product applications until the quality system violations were corrected.
The letter does not identify any specific concerns about the performance of the company's Riata ST Optim or Durata leads or any other St Jude Medical product, the company said.
St Jude said it would continue manufacturing and shipping products from the Sylmar facility, and that customer orders were not expected to be affected while it works to resolve the FDA's concerns.
- Russia criticizes EU sanctions, raps U.S. over Ukraine role |
- Israel says ready to extend short Gaza truce; many bodies pulled from rubble |
- First Ebola victim in Sierra Leone capital on the run
- Amazon's far-reaching ambitions, lack of profits, unnerve investors |
- Apple iPhones allow extraction of deep personal data, researcher finds